research

The National Multiple Sclerosis Society has granted $24.4 million to fund 64 multiple sclerosis (MS) research projects and training fellowships worldwide. This is the latest funding initiative by the Society, which is planning to invest a total of $35 million in 2019 to support 340 MS studies ongoing across…

Research finds that a deficiency of B vitamins may play a role in multiple sclerosis (MS) symptoms. On the other hand, supplementation of the vitamins may help. There are eight essential B vitamins: B1, B2, B3, B5, B6, B7, B9, and B12. The large variety can be confusing when…

Jeffrey Cohen, MD, director of the experimental therapeutics program at the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic, is the newly named  president of ACTRIMS, the Americas Committee for Treatment and Research in Multiple Sclerosis. Cohen’s appointment concluded the 2019 ACTRIMS Forum that ran…

Australian researchers from the University of Newcastle and the Hunter Medical Research Institute (HMRI) have received funding for two projects that will study unexplored areas in multiple sclerosis (MS). The projects, investigating the role of epigenetic differences in MS severity and treatment against MS-derived fatigue, received $211,000 AUD (about $151,300…

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about multiple sclerosis? Visit our forum. This week’s question is inspired by the forum topic “Can there be a connection between Epstein-Barr virus…

Katerina Akassoglou, PhD, a leading neurology researcher at the Gladstone Institutes at the University of California, San Francisco (UCSF), won the 2018 Barancik Prize for Innovation in Multiple Sclerosis Research. Akassoglou will receive the award and deliver the Prize lecture at the Americas Committee for Treatment…

To increase the exchange of research information and goings-on with the patient community, the Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) has teamed with RealTalk MS, a weekly podcast for those affected by the disease. Specifically, ACP will share ongoing results of its research initiative, iConquerMS. In…

The National Multiple Sclerosis Society (NMSS) has pledged $12 million to support 40 new, multi-year research projects focused on “stopping MS, restoring lost function, and ending the disease forever,” the organization announced in a press release. This commitment — the last allocation set aside for research in 2018 —…

Statistics show that men are three times less likely than women to develop multiple sclerosis. Research has shown that men also develop MS at a later age than women and that their disease is more progressive. Could this all be related to “low T,” or low testosterone? Researchers…

I’m a great starter. How about you? I start projects but often lack the time or motivation to finish them. Hence, I have bins full of yarn waiting to be turned into scarves and lots of seeds that were meant to be planted in the past growing seasons. It’s…

The National Multiple Sclerosis Society gave its Impact Award to Bianca Weinstock-Guttman, MD, for her research and patient care in multiple sclerosis (MS). According to the society, the award is intended for “a business or individual whose leadership helps ensure those with MS live their best lives.” Weinstock-Guttman…

Registrations are now open for the 32nd Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), set for May 30-June 2 at the Music City Center in Nashville, Tennessee. The CMSC Annual Meeting is the nation’s largest educational conference and professional development event for healthcare practitioners, researchers and…

Multiple Sclerosis News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other events dealing with multiple sclerosis throughout 2017. We look forward to providing more news to MS patients, family members, and caregivers during 2018. As a reminder of what mattered most to you in…

This year, I wrote several articles about gut health because, in addition to MS, that’s what I’m currently battling. Writing is cathartic, so when an issue hits close to home, pouring words onto paper … er, a laptop, is a godsend. It’s like having a…

Christmas is just around the corner, and that’s why many people are on the fruitless quest for Fingerlings or hocking an organ to buy the new iPhone. Both might be the “hot” presents of the season, but neither of them holds a candle to the great gifts we…

There are two doctors. Here’s your choice: One has a patient-centered approach to care, spends more time with you during appointments, and is more empathetic with your concerns. On average, patients under this doctor live longer. The other doctor spends less time in the appointment, struggles to listen…

I have every single malady associated with MS. I’m absolutely positive. Because whenever I find out about a new one, or a new study that says we don’t sleep well, or we twitch or tremble, or suffer from this deficiency or that, I’ve got it.

Fast Forward, a non-profit subsidiary of the National Multiple Sclerosis Society, will give financial support to TG Therapeutics to advance TGR-1202 (umbralisib) into preclinical testing as a potential oral therapy for progressive forms of multiple sclerosis. The support, whose value was not specified, is part of a Sponsored Research Agreement between Fast Forward and the company. Research work will be led by Lawrence Steinman, MD, a professor of pediatrics, neurology, and neurological sciences at Stanford University. TGR-1202 is an orally administrated inhibitor that blocks a signaling enzyme called PI3K delta. Immune cells such as B-cells have high levels of this enzyme, which is thought to be important for cell proliferation and survival. "We look forward to evaluating umbralisib [TGR-1202]'s effect on our preclinical progressive MS models in hopes to move umbralisib closer to clinical development in MS," Steinman said. The approval of Ocrevus (ocrelizumab), by Genentech, to treat primary progressive and relapsing multiple sclerosis underscored the potential of B-cell-targeted therapies for MS patients. As a result, investigative drugs that also aim to bolster B-cell survival or activity, such as those being developed by TG Therapeutics, are an attractive approach to potentially treating patients. Another potential treatment by the company — an engineered antibody, TG-1101 — targets a specific sequence on the CD20 protein found on immune B-cells. This infusion therapy is now in two Phase 3 clinical studies for relapsing multiple sclerosis, ULTIMATE I and ULTIMATE II. Both are currently enrolling patients at sites in Kentucky, Tennessee, and New York.

Do you ever stop and ponder the value of MS drugs? I’m not talking about if they work and the ways they improve our lives. I’m thinking of the COST of them and what their pricing means to investors. I get several market analysis reports on the pharmaceutical industry,…

The Multiple Sclerosis Association of America (MSAA) has released three new resources for people with multiple sclerosis (MS), available for free as both printed and online versions on MSAA’s website. According to a press release, the three new resources are: A cover story in the latest edition of MSAA’s…